Abcam, ab258148, Human PSME4 (Proteasome Activator Subunit 4) knockout HeLa cell lysate

Size: 1Kit
PSME4 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp deletion in exon2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp deletion in exon2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PSME4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Proteasome Activator Subunit 4 (PSME4) also known as PA200 is an important component in regulating protein degradation. It belongs to the family of proteasome activator subunits and has a molecular mass of approximately 230 kDa. PSME4 is mainly expressed in the nucleus of cells and modulates proteasome activity by binding to the proteasome core particle. Through facilitating protein breakdown PSME4 significantly influences various cellular processes including the elimination of oxidatively damaged proteins.
Biological function summary
PSME4 functions as part of a complex that enhances proteasome-mediated protein degradation. This complex formation improves the efficiency of protein processing by recruiting specific substrates for degradation. PSME4 is involved in DNA repair processes and plays a role in spermatogenesis contributing to proper cell cycle progression and genomic stability. The protein's activity in these biological functions demonstrates its importance in maintaining cellular homeostasis.
Pathways
PSME4 is intricately involved in the ubiquitin-proteasome pathway and the DNA damage response pathway which are essential for maintaining protein quality control and genomic integrity. PSME4 interacts with other proteins such as RAD23B facilitating the repair of damaged DNA. By integrating into these pathways PSME4 ensures the proper execution of critical cellular processes and responds to stress-related signals.
Alterations in PSME4 expression or function have connections to cancer progression and neurodegenerative diseases. In cancer PSME4 may influence tumor growth and resistance to therapy through its role in DNA repair and protein turnover. Additionally in neurodegenerative conditions like Alzheimer's disease PSME4-associated proteasome dysfunction contributes to the accumulation of toxic protein aggregates. Understanding PSME4 interactions with proteins like p53 in cancer or tau in neurodegeneration offers insights into potential therapeutic targets.